Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

L.A. McKeown

June 05, 2024

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

Michael O'Riordan

January 28, 2021

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Michael O'Riordan

November 12, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Daily News

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

Yael L. Maxwell

January 29, 2018

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

Advertisement

Statins Are Cost-effective in the Elderly

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Despite COVID-19, Heart Disease Remains Top US Killer: AHA

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Alirocumab Price Slashed in Deal With Express Scripts

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Evolocumab Not Cost-Effective at Current List Price

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content